Free tool
FAERS Monitor: Azasite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050810 or its brand name (Azasite, Azithromycin). Reports on generic versions are filed under their own applications.
Reports
1,475
Serious
351
24% of reports
Hospitalization
170
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event421
- drug dose omission329
- product quality issue276
- inappropriate schedule of drug administration211
- eye irritation195
- product packaging quantity issue146
- off label use143
- drug ineffective132
- eye pain105
- eye pruritus105
- dyspnoea102
- lacrimation increased91
- ocular hyperaemia91
- asthma82
- cough80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 16 |
| 2009 | 12 |
| 2010 | 14 |
| 2011 | 15 |
| 2012 | 201 |
| 2013 | 481 |
| 2014 | 43 |
| 2015 | 34 |
| 2016 | 64 |
| 2017 | 36 |
| 2018 | 39 |
| 2019 | 72 |
| 2020 | 118 |
| 2021 | 73 |
| 2022 | 65 |
| 2023 | 67 |
| 2024 | 39 |
| 2025 | 38 |
| 2026 | 45 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product packaging quantity issueSignal | 146 | 186.6 | 159.8 | 26,442 |
| eye irritationSignal | 195 | 48.5 | 42.5 | 9,013 |
| eye pruritusSignal | 105 | 44.7 | 37.2 | 4,435 |
| lacrimation increasedSignal | 91 | 43.1 | 35.3 | 3,692 |
| inappropriate schedule of drug administrationSignal | 211 | 42.4 | 37.4 | 8,495 |
| no adverse eventSignal | 421 | 33.2 | 30.6 | 13,202 |
| product quality issueSignal | 276 | 29.0 | 26.1 | 7,476 |
| drug dose omissionSignal | 329 | 28.4 | 25.8 | 8,732 |
| ocular hyperaemiaSignal | 91 | 27.4 | 22.4 | 2,289 |
| eye painSignal | 105 | 26.6 | 22.1 | 2,562 |
| asthmaSignal | 82 | 10.4 | 8.4 | 687 |
| coughSignal | 80 | 4.1 | 3.3 | 185 |
| dyspnoeaSignal | 102 | 2.6 | 2.1 | 99 |
| off label useSignal | 143 | 2.3 | 2.0 | 112 |
| drug ineffective | 132 | 1.4 | 1.2 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.